<DOC>
	<DOC>NCT01612286</DOC>
	<brief_summary>The investigators designed this study to evaluate the efficiency and the acute toxicities of recombinant human endostatin (endostar) combined with chemotherapy in the metastatic nasopharyngeal carcinoma (NPC).</brief_summary>
	<brief_title>Endostar Combination With Chemotherapy for the Metastatic Nasopharyngeal Carcinoma</brief_title>
	<detailed_description>To evaluate the progression free survival (PFS), overall survival (OS), Acute adverse reaction of recombinant human endostatin (endostar) combined with chemotherapy to the metastatic nasopharyngeal carcinoma (NPC).</detailed_description>
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Nasopharyngeal Neoplasms</mesh_term>
	<mesh_term>Endostatins</mesh_term>
	<criteria>Diagnosed metastatic NPC patient who have received radiotherapy or chemoradiotherapy with an at least 6 months interval Have measurable lesions No dysfunction of the major organs Can understand this study and give a signed informed consent certificates without a history of allergic reaction to the biological agents Pregnant or lactating women; Women of childbearing age without contraception with a Serious infection or dysfunction of the major organs have taken other antitumor drugs during the period of 30 days ahead of this clinical trial allergic to the Escherichia coli preparations Cann't understand this study and give a signed informed consent certificates</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>April 2013</verification_date>
	<keyword>Recombinant human endostatin</keyword>
	<keyword>nasopharyngeal carcinoma</keyword>
	<keyword>chemotherapy</keyword>
</DOC>